Anti-CA 19-9 CE/IVD for IHC - Gastrointestinal pathology

Anti-CA 19-9 CE/IVD for IHC - Gastrointestinal pathology

 

CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings.

 

 
 

 

Colon Cancer
Gastric carcinoma 

 

Search result : 6 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 3
  • human 3
  • Primary antibody
  • mouse 3
  • IHC 6
  • IHC065 3
  • IHC199 3
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
IHC199-100
 0.1ml,Concentrated 
IHC065-7
 7ml,Prediluted 
IHC065-1
 1ml,Concentrated 
IHC065-100
 0.1ml,Concentrated